2025
An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
Spigel D, Westeel V, Anderson I, Greillier L, Guisier F, Bylicki O, Badin F, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Gubens M, Crowley J, von der Leyen H, Woodard G, Kratz J, Jablons D, Mann M. An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay. Journal Of Clinical Oncology 2025, 43: lba8027-lba8027. DOI: 10.1200/jco.2025.43.17_suppl.lba8027.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease free survivalModified intent-to-treatAdjuvant chemotherapyCell lung cancerLung cancerInterim analysisCycles of platinum-based adjuvant chemotherapyNon-squamous non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized trials of adjuvant chemotherapyModified intent-to-treat populationTumor size > 4 cmNon-squamous NSCLC patientsRandomized to adjuvant chemotherapyTime of chemotherapy initiationMedian disease free survivalImproved disease free survivalPlatinum-based adjuvant chemotherapyTrials of adjuvant chemotherapyHigh riskRandomized to observationMedian Follow-UpPrimary lung cancerProspective randomized trials
2024
Living on the edge: Role of adjuvant therapy after resection of primary lung cancer within 2 millimeters of a T-stage cutoff
Udelsman B, Bedrosian C, Kawaguchi E, Ding L, Wallace W, Rosenberg G, Harano T, Wightman S, Atay S, Kim A, Woodard G. Living on the edge: Role of adjuvant therapy after resection of primary lung cancer within 2 millimeters of a T-stage cutoff. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 1338-1345.e15. PMID: 39521371, PMCID: PMC12034478, DOI: 10.1016/j.jtcvs.2024.10.053.Peer-Reviewed Original ResearchNon-small cell lung cancerSystemic therapyOverall survivalT stageTumor sizeResected non-small cell lung cancerLung cancerNational Cancer Database of patientsResection of primary lung cancerOutcomes of systemic therapyPathologic tumor sizeNational Cancer DatabaseAdjuvant therapy useUse of systemic therapyPrimary lung cancerResection of tumorsCell lung cancerAssociated with decreased ratesDatabase of patientsRetrospective cohort studyTumor size distributionDownstaged patientsNodal involvementUnder-stagingAdjuvant therapy
2023
GATA3 expression in primary lung carcinomas: correlation with histopathologic features and TTF-1, napsin A, and p40 expression
Wang M, Chen P, Cai G. GATA3 expression in primary lung carcinomas: correlation with histopathologic features and TTF-1, napsin A, and p40 expression. Human Pathology 2023, 135: 93-98. PMID: 36702357, DOI: 10.1016/j.humpath.2023.01.007.Peer-Reviewed Original ResearchConceptsLarge cell carcinomaPrimary lung carcinomaSarcomatoid carcinomaCell carcinomaNapsin ALung carcinomaGATA3 expressionTTF-1Non-small cell carcinomaNon-small cell lung carcinomaPrimary non-small cell lung carcinomasPrimary lung cancerSquamous cell carcinomaPanel of immunostainsCell lung carcinomaExpression of GATA3Whole-slide sectionsTMA casesAdenosquamous carcinomaTumor histologyHistopathologic featuresGATA3 stainingLung cancerP40 expressionTumor origin
2021
Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy
Raju SC, Peters GW, Decker RH, Park HS. Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2021, 12: e110-e116. PMID: 34861443, DOI: 10.1016/j.prro.2021.11.006.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyPrimary lung tumorsSynchronous primary lung tumorsAdverse events gradeCommon Terminology CriteriaBody radiation therapyLung tumorsNew primaryTerminology CriteriaOverall survivalClinical outcomesLung cancerRadiation therapyEvents gradeEarly-stage primary lung cancerMedian progression-free survivalEffective doseDistant failure ratesLocal failure rateMedian overall survivalMedian total dosePrimary lung cancerProgression-free survivalPatterns of recurrenceNonmetastatic lung cancerBreast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features
Wang B, Jiang Y, Li SY, Niu RL, Blasberg JD, Kaifi JT, Liu G, Wang ZL. Breast metastases from primary lung cancer: a retrospective case series on clinical, ultrasonographic, and immunohistochemical features. Translational Lung Cancer Research 2021, 0: 0-0. PMID: 34430360, PMCID: PMC8350075, DOI: 10.21037/tlcr-21-542.Peer-Reviewed Original ResearchPrimary lung cancerRetrospective case seriesBreast metastasisLung cancerCase seriesImmunohistochemical featuresCytokeratin 7Breast nodulesPrimary breast malignancyThyroid transcription factor-1Lung cancer metastasisAxillary lymphadenopathyClinical featuresLung metastasesImmunohistochemical findingsTranscription factor 1Ultrasonographic featuresBreast malignancyUltrasound featuresUltrasonographic characteristicsImmunohistochemical dataClinical practiceMetastasisNapsin A.CancerProlonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy.
Unlu S, Grant MJ, Gettinger S, Adeniran A, Kluger HM. Prolonged Complete Response of Early Stage Primary Adenocarcinoma of the Lung to Nivolumab Monotherapy. Clinical Oncology Case Reports 2021, 4 PMID: 34382032, PMCID: PMC8353529.Peer-Reviewed Original ResearchMultiple primary malignant tumorsNivolumab monotherapyCheckpoint inhibitorsLung cancerHigh Programmed-Death Ligand 1 (PD-L1) expressionProgrammed Death Ligand 1 ExpressionNon-small cell lung cancerMultiple regional lymph nodesImmune checkpoint inhibitorsPD-1 inhibitorsLigand 1 expressionPrimary lung cancerEarly-stage diseaseRegional lymph nodesCell lung cancerPrimary malignant tumorsHigh-risk natureSystemic immunotherapyDurable responsesAdvanced melanomaComplete responseEffective immunotherapyLymph nodesMore patientsPrimary adenocarcinoma
2020
26. GENETIC CHARACTERIZATION OF SELLAR METASTASIS FROM PRIMARY BRONCHIAL CARCINOID TUMOR OF NEUROENDOCRINE PATHOLOGY
Hong C, McGuone D, Erson-Omay E, Omay S. 26. GENETIC CHARACTERIZATION OF SELLAR METASTASIS FROM PRIMARY BRONCHIAL CARCINOID TUMOR OF NEUROENDOCRINE PATHOLOGY. Neuro-Oncology Advances 2020, 2: ii4-ii5. PMCID: PMC7401391, DOI: 10.1093/noajnl/vdaa073.016.Peer-Reviewed Original ResearchSellar metastasisCarcinoid tumorsSystemic tumorsNeuroendocrine tumorsPrimary tumorNeuroendocrine originSellar regionPituitary glandMultiple primary lung cancersSubsequent brain MRIPrimary lung cancerBronchial carcinoid tumorsLung carcinoid tumorYear old femaleKi-67 indexGenetic alterationsEndoscopic endonasal approachWhole-exome sequencingPituitary adenoma progressionFinal pathologyPituitary involvementPositive immunohistochemistryEndocrine dysfunctionHistopathological correlatesRare lesions
2019
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. Journal Of Clinical Oncology 2019, 38: 753-766. PMID: 31829901, DOI: 10.1200/jco.19.02748.Peer-Reviewed Original ResearchConceptsCurative-intent therapyLung cancerStage IFluorodeoxyglucose positron emission tomography/Evidence-based guideline recommendationsNew primary lung cancerRetrospective comparative observational studySurveillance strategiesSmall cell lung cancerBrain magnetic resonance imagingLiterature searchPositron emission tomography/Lung cancer surveillanceCurative-intent treatmentPrimary lung cancerRecurrence-free survivalCell lung cancerDetection of recurrenceComparative observational studyEmission tomography/Optimal imaging modalityEvidence-based recommendationsOutcomes of interestQuality of lifeMagnetic resonance imaging
2018
Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community
Su C, Bhargava A, Shah C, Halmos B, Gucalp R, Packer S, Ohri N, Haramati L, Perez-Soler R, Cheng H. Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community. Clinical Lung Cancer 2018, 19: e767-e773. PMID: 29937386, DOI: 10.1016/j.cllc.2018.05.019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedCarcinoma, Squamous CellCombined Modality TherapyDecision Support TechniquesEarly Detection of CancerFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMedically Underserved AreaMiddle AgedPrognosisRetrospective StudiesSmall Cell Lung CarcinomaSurvival RateTomography, X-Ray ComputedUrban PopulationConceptsUnited States Preventative Services Task Force guidelinesPrimary lung cancerTask Force guidelinesLung cancerScreening TrialMortality differencesPrimary care provider statusScreen-detected lung cancersNational Lung Screening TrialLung cancer-related mortalityLung Cancer Screening TrialActive smoking statusTime of diagnosisCancer Screening TrialCancer-related mortalityUnderserved communitiesUrban underserved communitiesLCS eligibilityCause mortalityPatient characteristicsProspective trialCurative treatmentSmoking statusSurgical managementCox regressionChapter 15 Diagnosis and Management of Treatment-Related Pulmonary Complications
Possick J. Chapter 15 Diagnosis and Management of Treatment-Related Pulmonary Complications. 2018, 221-241. DOI: 10.1016/b978-0-323-48565-4.00015-1.ChaptersLung cancerPulmonary complicationsPulmonary toxicityGenotype-directed targeted therapyPossible treatment-related complicationsSecond primary lung cancerEarly-stage lung cancerRadiation-induced pulmonary toxicityAppropriate clinical presentationNew pulmonary symptomsPotential treatment complicationsTreatment-related complicationsTreatment-related toxicityPrimary lung cancerDiagnosis of exclusionPrior surgical resectionManagement of treatmentManagement of individualsGold standard testABSTRACT ComplicationsPulmonary comorbiditiesPulmonary reserveAdvanced diseasePulmonary symptomsSystemic chemotherapy
2017
Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung
Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA. Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal Of Thoracic Oncology 2017, 13: 205-217. PMID: 29127023, PMCID: PMC6276791, DOI: 10.1016/j.jtho.2017.10.019.Peer-Reviewed Original ResearchConceptsSecond primary lung cancerIntrapulmonary metastasesComprehensive histologic assessmentHistologic featuresHistologic patternLung pathologistsHistologic assessmentNuclear pleomorphismMitotic rateSeparate primary tumorsPrimary lung cancerMain histologic typesPredominant patternDistinctive histologic featuresMultiple tumor nodulesClear cell changeRefinement of criteriaLepidic growthHistologic subtypeHistologic typeVascular invasionPrimary tumorLung cancerTumor extentLung tumors
2016
Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions
Gao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, Huffman K, Oliver D, Kinose F, Haura E, Teer JK, Rix U, Le AT, Aisner DL, Varella-Garcia M, Doebele RC, Covington KR, Hampton OA, Doddapaneni HV, Jayaseelan JC, Hu J, Wheeler DA, Shay JW, Rimm DL, Gazdar A, Minna JD. Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 2016, 5: 11114-11126. PMID: 28052041, PMCID: PMC5355251, DOI: 10.18632/oncotarget.14366.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAdultAgedAged, 80 and overBase SequenceCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationCells, CulturedCoculture TechniquesDNA Copy Number VariationsDNA Mutational AnalysisEpithelial CellsFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMiddle AgedMutationRespiratory MucosaTumor Cells, CulturedConceptsNon-small cell lung cancerRespiratory epithelial cellsNon-malignant lungCell lung cancerCRC culturesLung cancerEpithelial cellsResected non-small cell lung cancerPrimary lung cancerNon-malignant samplesLung epithelial cellsRho-kinase inhibitorNon-malignant cellsPrimary NSCLCPrimary tumorDiploid patternOriginal tumorTumor specimensTumor tissueTumorsKinase inhibitorsCancerCancer cellsMRNA expression profilesSmall subpopulationVideo-Assisted Thoracoscopic Lobectomy for Lung Cancer: Current Practice Patterns and Predictors of Adoption
Blasberg JD, Seder CW, Leverson G, Shan Y, Maloney JD, Macke RA. Video-Assisted Thoracoscopic Lobectomy for Lung Cancer: Current Practice Patterns and Predictors of Adoption. The Annals Of Thoracic Surgery 2016, 102: 1854-1862. PMID: 27592603, DOI: 10.1016/j.athoracsur.2016.06.030.Peer-Reviewed Original ResearchConceptsPrimary lung cancerLung cancerIndependent predictorsSurgeon volumeVATS lobectomyPractice patternsThoracic surgeonsVideo-assisted thoracoscopic surgery lobectomyVideo-Assisted Thoracoscopic LobectomyPremier hospital dataVATS lobectomy proceduresCentralization of careCurrent practice patternsStrong independent predictorThoracoscopic surgery lobectomyHigh-volume surgeonsLobectomy ratePostoperative complicationsClinical characteristicsSecondary outcomesOncologic efficacySurgical managementThoracoscopic lobectomyOpen lobectomyHospital typeThe IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Detterbeck FC, Bolejack V, Arenberg DA, Crowley J, Donington JS, Franklin WA, Girard N, Marom EM, Mazzone PJ, Nicholson AG, Rusch VW, Tanoue LT, Travis WD, Asamura H, Rami-Porta R, Committee I, Goldstraw P, Rami-Porta R, Asamura H, Ball D, Beer D, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Eberhardt W, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim Y, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom E, van Meerbeeck J, Mitchell A, Nakano T, Nicholson A, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier J, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas C, Travis W, Tsao M, Turrisi A, Vansteenkiste J, Watanabe H, Wu Y, Boards A, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso P, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Workgroup M, Flieder D, Godoy M, Goo J, Goodman L, Jett J, de Leyn P, Marchevsky A, MacMahon H, Naidich D, Okada M, Perlman M, Powell C, van Schil P, Warth A, Institutions P, Cavaco F, Barrera E, Arca J, Lamelas I, Obrer A, Jorge R, Ball D, Bascom G, Orozco A, Castro M, Blum M, Chimondeguy D, Cvijanovic V, Defranchi S, de Olaiz Navarro B, Campuzano I, Vidueira I, Araujo E, García F, Fong K, Corral G, González S, Gilart J, Arangüena L, Barajas S, Girard P, Goksel T, Budiño M, Casaurrán G, Blanco J, Hernández J, Rodríguez H, Collantes J, Heras M, Elena J, Jakobsen E, Kostas S, Atance P, Ares A, Liao M, Losanovscky M, Lyons G, Magaroles R, De Esteban Júlvez L, Gorospe M, McCaughan B, Kennedy C, Íñiguez R, Sorribes L, Gozalo S, de Arriba C, Delgado M, Alarcón J, Cuesta J, Park J, Pass H, Fernández M, Rosenberg M, Ruffini E, Rusch V, de Cos Escuín J, Vinuesa A, Mitjans M, Strand T, Subotic D, Swisher S, Terra R, Thomas C, Tournoy K, Van Schil P, Velasquez M, Wu Y, Yokoi K. The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2016, 11: 681-692. PMID: 26940530, DOI: 10.1016/j.jtho.2015.12.114.Peer-Reviewed Original ResearchConceptsSeparate tumor nodulesPrimary lung cancerLung cancerTumor nodulesEighth editionTNM classificationSurvival differencesSecond primary lung cancerIASLC Lung Cancer Staging ProjectLung Cancer Staging ProjectForthcoming Eighth EditionSame histologic appearanceProportion of patientsSurvival of patientsLung cancer databaseT3 tumorsT4 tumorsIndex tumorCancer DatabaseSuch tumorsHistologic appearanceAnatomic classificationPatientsTumorsCancerThe IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification
Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, Arenberg DA, Bolejack V, Donington JS, Mazzone PJ, Tanoue LT, Rusch VW, Crowley J, Asamura H, Rami-Porta R, Committee I, Goldstraw P, Rami-Porta R, Asamura H, Ball D, Beer D, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Eberhardt W, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim Y, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom E, van Meerbeeck J, Mitchell A, Nakano T, Nicholson A, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier J, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas C, Travis W, Tsao M, Turrisi A, Vansteenkiste J, Watanabe H, Wu Y, Boards A, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso P, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Workgroup M, Flieder D, Godoy M, Goo J, Goodman L, Jett J, de Leyn P, Marchevsky A, MacMahon H, Naidich D, Okada M, Perlman M, Powell C, van Schil P, Warth A, Institutions P, Cavaco F, Barrera E, Arca J, Lamelas I, Obrer A, Jorge R, Ball D, Bascom G, Orozco A, Castro M, Blum M, Chimondeguy D, Cvijanovic V, Defranchi S, de Olaiz Navarro B, Campuzano I, Vidueira I, Araujo E, García F, Fong K, Corral G, González S, Gilart J, Arangüena L, Barajas S, Girard P, Goksel T, Budiño M, Casaurrán G, Blanco J, Hernández J, Rodríguez H, Collantes J, Heras M, Elena J, Jakobsen E, Kostas S, Atance P, Ares A, Liao M, Losanovscky M, Lyons G, Magaroles R, De Esteban Júlvez L, Gorospe M, McCaughan B, Kennedy C, Íñiguez R, Sorribes L, Gozalo S, de Arriba C, Delgado M, Alarcón J, Cuesta J, Park J, Pass H, Fernández M, Rosenberg M, Ruffini E, Rusch V, de Cos Escuín J, Vinuesa A, Mitjans M, Strand T, Subotic D, Swisher S, Terra R, Thomas C, Tournoy K, Van Schil P, Velasquez M, Wu Y, Yokoi K. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. Journal Of Thoracic Oncology 2016, 11: 639-650. PMID: 26940528, DOI: 10.1016/j.jtho.2016.01.024.Peer-Reviewed Original ResearchConceptsMultiple pulmonary sitesLung cancerPulmonary sitesM categoryTNM classificationSecond primary lung cancerEighth editionIASLC Lung Cancer Staging ProjectLung Cancer Staging ProjectForthcoming Eighth EditionSame histologic typePrimary lung cancerLung cancer stagingLung cancer databaseSeparate tumor nodulesArea of involvementPatterns of diseasePrognostic Factors CommitteeClinical presentationHistologic typePathologic correlatesMetastasis classificationOptimal treatmentT categoryCancer DatabaseThe IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Detterbeck FC, Franklin WA, Nicholson AG, Girard N, Arenberg DA, Travis WD, Mazzone PJ, Marom EM, Donington JS, Tanoue LT, Rusch VW, Asamura H, Rami-Porta R, Committee I, Goldstraw P, Rami-Porta R, Asamura H, Ball D, Beer D, Beyruti R, Bolejack V, Chansky K, Crowley J, Detterbeck F, Eberhardt W, Edwards J, Galateau-Sallé F, Giroux D, Gleeson F, Groome P, Huang J, Kennedy C, Kim J, Kim Y, Kingsbury L, Kondo H, Krasnik M, Kubota K, Lerut A, Lyons G, Marino M, Marom E, van Meerbeeck J, Mitchell A, Nakano T, Nicholson A, Nowak A, Peake M, Rice T, Rosenzweig K, Ruffini E, Rusch V, Saijo N, Van Schil P, Sculier J, Shemanski L, Stratton K, Suzuki K, Tachimori Y, Thomas C, Travis W, Tsao M, Turrisi A, Vansteenkiste J, Watanabe H, Wu Y, Boards A, Baas P, Erasmus J, Hasegawa S, Inai K, Kernstine K, Kindler H, Krug L, Nackaerts K, Pass H, Rice D, Falkson C, Filosso P, Giaccone G, Kondo K, Lucchi M, Okumura M, Blackstone E, Workgroup M, Flieder D, Godoy M, Goo J, Goodman L, Jett J, de Leyn P, Marchevsky A, MacMahon H, Naidich D, Okada M, Perlman M, Powell C, van Schil P, Warth A. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal Of Thoracic Oncology 2016, 11: 651-665. PMID: 26944304, DOI: 10.1016/j.jtho.2016.01.025.Peer-Reviewed Original ResearchConceptsPrimary lung cancerSecond primary lung cancerSeparate primary lung cancersLung cancerIASLC Lung Cancer Staging ProjectLung Cancer Staging ProjectForthcoming Eighth EditionOutcomes of patientsMultidisciplinary tumor boardLung cancer stagingComprehensive histologic assessmentHistologic cancer typesAbsence of biomarkersMechanisms of metastasisPrognostic Factors CommitteeNodal involvementTNM classificationMetastatic fociPathologic criteriaPulmonary sitesSecond primaryHistologic assessmentTumor boardCancer stagingLung tumorsWhole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas
Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget 2016, 7: 8321-8331. PMID: 26824986, PMCID: PMC4884995, DOI: 10.18632/oncotarget.7032.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternExomeFemaleGenome, HumanHigh-Throughput Nucleotide SequencingHistone-Lysine N-MethyltransferaseHumansImmunoenzyme TechniquesLoss of HeterozygosityLung NeoplasmsMesotheliomaMesothelioma, MalignantMiddle AgedMutationPleural NeoplasmsPrognosisProtein MethyltransferasesReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsMalignant pleural mesotheliomaPrimary cancerPleural mesotheliomaGenetic mechanismsDeep sequencingAdditional primary cancersMultiple primary cancersPrimary lung cancerPrimary cancer developmentAllelic lossNew genetic mechanismWhole-exome sequencingDistinct genomic alterationsMPM patientsRare malignancyPerineural invasionPoor prognosisTherapeutic optionsLung cancerLoss of heterozygosityTP53 mutationsCancer developmentPatientsExome sequencingCancer
2015
Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy
Harder EM, Park HS, Nath SK, Mancini BR, Decker RH. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy. Practical Radiation Oncology 2015, 5: e643-e649. PMID: 26412341, DOI: 10.1016/j.prro.2015.07.003.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyACE inhibitor useNonsteroidal anti-inflammatory drugsAngiotensin receptor blockersRadiation pneumonitisSymptomatic radiation pneumonitisInhibitor useBody radiation therapyAnti-inflammatory drugsRadiation therapyReceptor blockersACE inhibitorsAngiotensin-converting enzyme inhibitor useACE inhibitor usersCommon Terminology CriteriaEnzyme inhibitor usePrimary lung cancerNormal lung tissuesAvailable medical recordsCox proportional hazardsPulmonary doseTerminology CriteriaInhibitor usersAdverse eventsOverall survival
2014
Metastatic squamous cell carcinoma presenting as an erythematous nodule in a man with lung adenocarcinoma.
Korta D, Lewin J, Meehan S, Ramachandran S. Metastatic squamous cell carcinoma presenting as an erythematous nodule in a man with lung adenocarcinoma. Journal Of Drugs In Dermatology 2014, 13: 1277-9. PMID: 25607566.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLung cancerSkin lesionsSkin metastasesPrimary malignancyCell carcinomaLung adenocarcinomaMetastatic squamous cell carcinomaSecond primary lung cancerSquamous cell carcinoma presentingNovel chemotherapeutic regimenOccult internal malignancyRetroperitoneal lymph nodesSecond primary malignanciesPatient's skin lesionsPoor prognostic signPrimary lung cancerMetastatic lung adenocarcinomaMetastatic skin lesionsCutaneous metastasesVisceral cancerCarcinoma presentingChemotherapeutic regimenVisceral malignancyInternal malignancyManagement of Clinical Stage IIIA Primary Lung Cancers in the National Cancer Database
Hancock J, Rosen J, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Management of Clinical Stage IIIA Primary Lung Cancers in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 98: 424-432. PMID: 24929895, DOI: 10.1016/j.athoracsur.2014.04.067.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseClinical stagingMediastinal stagingLung cancerCancer DatabaseClinical stage IIIA non-small cell lung cancerStage IIIA non-small cell lung cancerIIIA non-small cell lung cancerTreatment approachesMediastinal lymph node diseaseMediastinal lymph node metastasisClinical N2 statusTreatment-naïve patientsLymph node diseasePrimary lung cancerUse of surgeryIIIA NSCLC patientsLymph node metastasisCell lung cancerOptimal treatment approachCommon treatment approachNaïve patientsUntreated patientsMediastinal lymph
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply